首页> 美国卫生研究院文献>IOS Press Open Library >Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery
【2h】

Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery

机译:凝血酶生成测试在冠状动脉搭桥手术中监测止血的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To evaluate the parameters of the thrombin generation test (TGT) in coronary artery disease (CAD) patients on prolonged aspirin therapy during on-pump coronary artery bypass grafting (CABG) after donor platelet concentrate transfusion. A total of 148 patients with CAD on prolonged aspirin therapy (75–100 mg/day) who have undergone elective on-pump CABG were consecutively included in the study. Patients were divided randomly into two groups. Group 1 (n = 76) received donor platelet transfusions after cardiopulmonary bypass, whereas Group 2 (n = 72) did not. TGT parameters were measured using an analyzer at pre-, intra-, and early postoperative periods. Activation of the endogenous thrombin potential was observed in patients on prolonged aspirin therapy in the pre- and intraoperative periods, as confirmed by high peak thrombin and increased velocity index. The activation time of the prothrombinase complex and thrombin generation time were greater than the control group. The blood hemostatic potential in patients who did not receive transfusions in the early postoperative period decreased up to the level of the control group in the extended time parameters. Hemostatic potential in plasma in patients on aspirin was preserved. Given the laboratory test results and clinical data, platelet concentrate transfusion is unnecessary for prevention.
机译:为了评估在供体血小板浓缩液输注后泵上冠状动脉搭桥术(CABG)期间接受长期阿司匹林治疗的冠状动脉疾病(CAD)患者中凝血酶生成测试(TGT)的参数。该研究连续纳入了148例接受长期阿司匹林治疗(75–100μmg /天)的CAD患者,这些患者接受了选择性泵上CABG治疗。将患者随机分为两组。第1组(n = 76)在体外循环后接受了供体血小板输注,而第2组(n = 72)则没有接受。在术前,术中和术后早期使用分析仪测量TGT参数。术前和术中长期接受阿司匹林治疗的患者观察到内源性凝血酶潜能的激活,这一现象已被高峰值凝血酶和增高的速度指数所证实。凝血酶原酶复合物的激活时间和凝血酶生成时间均大于对照组。术后早期未输血的患者的止血潜力下降至延长时间参数中对照组的水平。服用阿司匹林的患者血浆中具有止血潜力。根据实验室测试结果和临床数据,无需进行浓缩血小板输注。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号